Recruitment

Recruitment Status
Completed

Inclusion Criteria

LDL > or = 130 mg/dl - measured during screening
CVS Caremark Beneficiary
Medication Possession Ratio (MPR) <80%
...
LDL > or = 130 mg/dl - measured during screening
CVS Caremark Beneficiary
Medication Possession Ratio (MPR) <80%
Diabetes and or history of CVD
A prescription filled for statin medication within the last 12 months

Exclusion Criteria

Contraindication to further statin use or have suffered side effects from statins, such as myopathy
History of active or progressive liver disease or abnormal liver function tests on baseline screening
Less than 18 years old
...
Contraindication to further statin use or have suffered side effects from statins, such as myopathy
History of active or progressive liver disease or abnormal liver function tests on baseline screening
Less than 18 years old
Co-morbidities likely to lead to death within a short-period
Currently participating in another clinical trial with related aims
Will not or cannot give consent

Summary

Conditions
Diabetes
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Investigator)
  • Primary Purpose: Other

Participation Requirements

Age
Between 18 years and 80 years
Gender
Both males and females

Inclusion Criteria

LDL > or = 130 mg/dl - measured during screening
CVS Caremark Beneficiary
Medication Possession Ratio (MPR) <80%
...
LDL > or = 130 mg/dl - measured during screening
CVS Caremark Beneficiary
Medication Possession Ratio (MPR) <80%
Diabetes and or history of CVD
A prescription filled for statin medication within the last 12 months

Exclusion Criteria

Contraindication to further statin use or have suffered side effects from statins, such as myopathy
History of active or progressive liver disease or abnormal liver function tests on baseline screening
Less than 18 years old
...
Contraindication to further statin use or have suffered side effects from statins, such as myopathy
History of active or progressive liver disease or abnormal liver function tests on baseline screening
Less than 18 years old
Co-morbidities likely to lead to death within a short-period
Currently participating in another clinical trial with related aims
Will not or cannot give consent

Tracking Information

NCT #
NCT02086539
Collaborators
  • Rutgers University
  • National Institute on Aging (NIA)
Investigators
  • Principal Investigator: Kevin G Volpp, MD, PhD University of Pennsylvania
  • Kevin G Volpp, MD, PhD University of Pennsylvania